129 related articles for article (PubMed ID: 31177586)
1. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Shimozato N; Namisaki T; Kaji K; Kitade M; Okura Y; Sato S; Moriya K; Seki K; Kawaratani H; Takaya H; Sawada Y; Saikawa S; Nakanishi K; Furukawa M; Fujinaga Y; Kubo T; Asada K; Kitagawa K; Tsuji Y; Kaya D; Ozutsumi T; Akahane T; Mitoro A; Yoshiji H
Hepatol Res; 2019 Oct; 49(10):1147-1161. PubMed ID: 31177586
[TBL] [Abstract][Full Text] [Related]
2. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.
Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Okura Y; Shimozato N; Sato S; Nishimura N; Seki K; Kawaratani H; Takaya H; Sawada Y; Akahane T; Saikawa S; Nakanishi K; Kubo T; Furukawa M; Noguchi R; Asada K; Kitagawa K; Ozutsumi T; Tsuji Y; Kaya D; Fujinaga Y; Yoshiji H
Hepatol Commun; 2017 Nov; 1(9):928-945. PubMed ID: 29404501
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Okura Y; Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Noguchi R; Nishimura N; Seki K; Kawaratani H; Takaya H; Sato S; Sawada Y; Shimozato N; Furukawa M; Nakanishi K; Saikawa S; Kubo T; Asada K; Yoshiji H
Hepatol Res; 2017 Nov; 47(12):1317-1328. PubMed ID: 28029729
[TBL] [Abstract][Full Text] [Related]
6. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Sawada Y; Kawaratani H; Kubo T; Fujinaga Y; Furukawa M; Saikawa S; Sato S; Seki K; Takaya H; Okura Y; Kaji K; Shimozato N; Mashitani T; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yamao J; Yoshiji H
Hepatol Res; 2019 Mar; 49(3):284-295. PubMed ID: 30365236
[TBL] [Abstract][Full Text] [Related]
7. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
[TBL] [Abstract][Full Text] [Related]
8. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
10. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis.
Zhou J; Huang N; Guo Y; Cui S; Ge C; He Q; Pan X; Wang G; Wang H; Hao H
Acta Pharm Sin B; 2019 May; 9(3):526-536. PubMed ID: 31193776
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.
Kaji K; Yoshiji H; Ikenaka Y; Noguchi R; Aihara Y; Douhara A; Moriya K; Kawaratani H; Shirai Y; Yoshii J; Yanase K; Kitade M; Namisaki T; Fukui H
J Gastroenterol; 2014 Mar; 49(3):481-91. PubMed ID: 23475323
[TBL] [Abstract][Full Text] [Related]
12. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis.
Tawfiq RA; Nassar NN; Hammam OA; Allam RM; Elmazar MM; Abdallah DM; Attia YM
Chem Biol Interact; 2022 Jul; 361():109953. PubMed ID: 35439472
[TBL] [Abstract][Full Text] [Related]
14. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
Matye DJ; Qin X; Hasan MN; Gu L; Clayton YD; Li F; Li T
Liver Res; 2022 Dec; 6(4):276-283. PubMed ID: 36819659
[TBL] [Abstract][Full Text] [Related]
15. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
16. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
17. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
[TBL] [Abstract][Full Text] [Related]
18. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
19. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line.
Nakano S; Nagasawa T; Ijiro T; Inada Y; Tamura T; Maruyama K; Kuroda J; Yamazaki Y; Kusama H; Shibata N
Hepatol Res; 2008 Oct; 38(10):1026-39. PubMed ID: 18513333
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
